Sanne de Bruin

63 Transfusion practice in the bleeding critically ill; an international online survey – The TRACE-2 Survey Table 2. (continued) No. of respondents(%) How do you correct a plasmatic coagulopathy in critically ill patients with massive blood loss who used direct oral anti-coagulants(DOACs)? Vitamin K 92(23%) Prothrombin complex (Cofact/Octoplex/Beriplex) 273(68%) Plasma 256(64%) Recombinant factor VIIa (Novoseven/Eptacog alfa) 68(17%) Idarucizumab (for dabigatran) 194(48%) Andexanet (for rivaroxaban or apixaban) 84(21%) Nothing 6(1%) Other 28(7%) What guides your use of fibrinogen in critically ill patients with massive bleeding? I administer fibrinogen after lab testing (fibrinogen level) 146(36%) I administer fibrinogen after viscoelastic testing (TEG/ROTEM) 78(19%) I empirically administer fibrinogen 43(11%) I empirically administer fibrinogen, but start titrating when first lab results are available 121(30%) Other 12(3%) What guides your use of prothrombin complex (Cofact,Octoplex,Beriplex) in critically ill patients with massive bleeding. I administer prothrombin complex after lab testing (PT/INR) 157(39%) I administer prothrombin complex after viscoelastic testing (TEG/ROTEM) 91(23%) I empirically administer prothrombin complex 24(6%) I empirically administer prothrombin complex, but start titrating when first lab results are available 85(21%) Other (please specify) 40(10%) Do you use tranexamic acid in critically ill patients with massive bleeding? Yes 374(93%) No 26(6%) What guides your use of tranexamic acid in critically ill patients with massive bleeding? I administer tranexamic acid after viscoelastic testing (TEG/ROTEM) 33(8%) I empirically administer tranexamic acid 332(83%) Other 9(2%) 3